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The live-attenuated influenza vaccine (LAIV) has generally been more efficacious than the 
inactivated vaccine in children. However, LAIV is not recommended for HIV-infected chil-
dren because of insufficient data. We compared cellular, humoral, and mucosal immune 
responses to the 2013–2014 LAIV quadrivalent (LAIV4) in HIV-infected and uninfected chil-
dren 2–25 years of age (yoa). We analyzed the responses to the vaccine H1N1 (H1N1-09), 
to the circulating H1N1 (H1N1-14), which had significant mutations compared to H1N1-09 
and to B Yamagata (BY), which had the highest effectiveness in 2013–2014. Forty-six 
HIV-infected and 56 uninfected participants with prior influenza immunization had blood 
and nasal swabs collected before and after LAIV4 for IFNγ T and IgG/IgA memory B-cell 
responses (ELISPOT), plasma antibodies [hemagglutination inhibition (HAI) and microneu-
tralization (MN)], and mucosal IgA (ELISA). The HIV-infected participants had median CD4+ 
T cells = 645 cells/μL and plasma HIV RNA = 20 copies/mL. Eighty-four percent were on 
combination anti-retroviral therapy. Regardless of HIV status, significant increases in T-cell 
responses were observed against BY, but not against H1N1-09. H1N1-09 T-cell immunity 
was higher than H1N1-14 both before and after vaccination. LAIV4 significantly increased 
memory IgG B-cell immunity against H1N1-14 and BY in uninfected, but not in HIV-infected 
participants. Regardless of HIV status, H1N1-09 memory IgG B-cell immunity was higher 
than H1N1-14 and lower than BY. There were significant HAI titer increases after vaccination 
in all groups and against all viruses. However, H1N1-14 MN titers were significantly lower than 
H1N1-09 before and after vaccination overall and in HIV-uninfected vaccinees. Regardless 
of HIV status, LAIV4 increased nasal IgA concentrations against all viruses. The fold-increase 
in H1N1-09 IgA was lower than BY. Overall, participants <9 yoa had decreased BY-specific 
HAI and nasal IgA responses to LAIV4. In conclusion, HIV-infected and uninfected children 
and youth had comparable responses to LAIV4. H1N1-09 immune responses were lower 
than BY and higher than H1N1-14, suggesting that both antigenic mismatches between 
circulating and vaccine H1N1 and lower immunogenicity of the H1N1 vaccine strain may 
have contributed to the decreased H1N1 effectiveness of 2013–2014 LAIV4.
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inTrODUcTiOn
Influenza causes seasonal disease in temperate climate areas. It 
is estimated that 5–20% of the population of the US becomes 
infected with influenza yearly; >200,000 individuals are hospital-
ized with severe complications; and about 36,000 individuals die 
annually from influenza-related illness (1). Seasonal influenza 
vaccines are the mainstay of protection against the influenza and 
its complications.
The efficacy of the seasonal influenza vaccines depends primar-
ily on the match between the vaccine and the circulating viruses, 
although heterosubtypic cross-reactivity is well documented (2). 
In addition, the immune status of the host and the use of live-
attenuated or inactivated virus and of adjuvants also contribute 
to the immunogenicity and efficacy of the influenza vaccines. 
Influenza vaccines are least immunogenic at the extremes of 
age and in immune compromised hosts.1 The protective effect 
of inactivated influenza vaccines (IIV) correlates with antibody 
responses to the vaccines, such that a hemagglutination inhibi-
tion (HAI) antibody titer ≥40 is associated with a 50% decrease 
in the incidence of symptomatic disease in young adults (3). Less 
is known about other age groups, but HAI titers ≥40 are used as 
a benchmark for licensure of influenza vaccines.
In children, the live-attenuated influenza vaccine (LAIV) has 
repeatedly shown increased efficacy compared with IIV against 
both matched and drifted strains (4–6). Unlike IIV, LAIV does 
not have a well-established immune correlate of protection, but 
previous studies showed that cell-mediated immunity (7, 8) and/
or mucosal IgA (9, 10) contribute to LAIV-conferred protection. 
However, these parameters have not been validated and are not cur-
rently used to predict the potential effectiveness of LAIV in hosts 
with different levels of immune competence or in different seasons.
Live-attenuated influenza vaccine has warnings and precau-
tions for HIV-infected and other immune compromised hosts, but 
its use is not contraindicated in HIV-infected children. There are 
limited data on the safety, immunogenicity, and efficacy of LAIV 
in immune compromised hosts and strong concerns that LAIV 
may cause prolonged viral shedding and serious adverse events 
in these individuals. We and others showed that HIV-infected 
and uninfected children have similar amounts and duration of 
influenza vaccine viral shedding and similar antibody responses 
to LAIV (11, 12). By contrast, HIV-infected children mount poor 
antibody responses to IIV (13–16). Efficacy of IIV3 has not been 
studied in HIV-infected children in the US, but it was poor in 
HIV-infected children in South Africa (15), making LAIV an 
attractive candidate for protecting this group from influenza.
We studied the safety and immunogenicity of the quadriva-
lent LAIV (LAIV4) in HIV-infected children and adolescents 
compared with uninfected controls vaccinated between August 
and November of 2013. In the 2013–2014 influenza season, the 
circulating influenza A H1N1 (H1N1-14) had multiple mutations 
compared with the influenza A H1N1 in the vaccine (H1N1-09), 
including a mutation in an HA epitope targeted by human neu-
tralizing antibodies (17–20). In addition, the H1N1 component in 
1 http://www.cdc.gov/flu/about/disease/high_risk.htm
LAIV4 was temperature-sensitive so that its immunogenicity was 
greatly reduced in lots exposed to environmental temperatures 
≥80°F.2 This translated into lower effectiveness of the 2013–2014 
LAIV4 against H1N1 in the US, when most of the vaccine was 
shipped in late summer and early fall, but not in Canada where 
the vaccine was shipped later in the season (see text foot note 
2). 2013–2014 LAIV4 had excellent efficacy against B Yamagata 
(BY), the other influenza strain that caused disease in 2013–2014 
in the US and elsewhere. The LAIV4 used in our study was 
shipped directly from MedImmune in August of 2013.
We previously reported that LAIV4 was not associated with 
any serious adverse events and that viral shedding and antibody 
responses did not differ between HIV-infected and uninfected 
participants (21). Here, we report cellular responses to LAIV4, 
including effector T-cell and memory B-cell responses, in these 
children and a more detailed analysis of their antibody responses, 
including differences to the H1N1-09 with H1N1-14 and with BY.
ParTiciPanTs anD MeThODs
study Design
The study planned to enroll 110 subjects who were 2–25 years 
of age between July and October 2014 with the goal of retaining 
≥100 participants for ≥42  days post-immunization. The study 
was reviewed and approved by the institutional review board. 
Participants and/or legal guardians provided informed consent 
and/or assent. Inclusion criteria for HIV-infected participants 
were CD4 >15% or 200 cells/μL if receiving combination anti-
retroviral therapy (cART); or >25% or 500  cells/μL if not on 
cART. There were no HIV plasma RNA criteria for enrollment.
At entry, participants received a dose of LAIV4 containing live-
attenuated influenza A H1N1 California 2009, A H3N2 Victoria 
2011, B Massachusetts 2012 Yamagata lineage and B Brisbane 
2008 of Victoria lineage. Nasopharyngeal samples for influenza 
IgA antibodies were collected using flocked swabs (Copan) pre-
vaccination and on study days 2–5, 7–10, and 14–21. Blood was 
obtained pre-vaccination and at 14–21 days.
Propagation of influenza Viruses in 
embryonated eggs
A clinical H1N1-14 virus was isolated in Madin-Darby canine 
kidney (MDCK) tissue culture tubes as previously described (3). 
The virus stock, consisting of the tissue culture supernatant, was 
expanded by inoculation into the allantoic cavity of 11-day-old 
specific pathogen-free (SPF) embryonated hen eggs (Charles 
River Laboratories, North Franklin, CT, USA) and grown at 
37°C for 48 h. The allantoic fluid was harvested after cooling eggs 
overnight at 4°C, tested for hemagglutinating activity, and stored 
at −80°C in multiple aliquots. The 50% tissue culture infectious 
dose (TCID50) for each virus was determined by serial dilution 
of virus in MDCK cells. BY and H1N1-09 viruses were obtained 
from the influenza reagent repository at ATCC and expanded in 
embryonated eggs as above.
2 http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2015-
02.pdf
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ha gene sequencing
Viral RNA from H1N1-09 and H1N1-14 was isolated using 
the QIAamp Viral RNA Mini Kit (Qiagen, Germany). RNA 
concentration was measured via the Nanodrop ND-1000 
Spectrophotometer (Thermoscientific, MA, USA). Subsequently, 
1  μg of isolated RNA was used for cDNA synthesis using 
Superscript II (Invitrogen, Life Technologies, CA, USA). Briefly, 
RNA samples were incubated at 65°C for 5 min with 1 μL dNTPs 
(10  mM each) (Invitrogen, Life Technologies, CA, USA) and 
1 μL of random hexamers (Invitrogen, Life Technologies, CA, 
USA). Following that, a mastermix of 4  μL of 5× first strand 
buffer, 1 μL of DTT (Invitrogen, Life Technologies, CA, USA), 
and 1  μL of RNAseOUT (Invitrogen, Life Technologies, CA, 
USA) was added, then incubated at 25°C for 2 min. Then, 1 μL 
of SuperScript II Reverse Transcriptse enzyme (Invitrogen, Life 
Technologies, CA, USA) was added, and incubated at 25°C for 
10 min, 42°C for 50 min, and finally 70°C for 15 min. In order 
to analyze mutations located within the HA gene, we designed 
and employed two internal primers for PCR amplification 
and sequencing of a 500 base fragment flanking amino acid 
residue 166: HA280F (5′-TCCTACATTGTGGAAACATCT-3′) 
and HA780R (5′-TTCGAATGTTATTTTGTCTCC-3′). PCR 
amplification (ABI 2700, Applied Biosystems, CA, USA) used a 
protocol of 94°C for 6 min, followed by 40 cycles of: 94°C for 30 s, 
53°C for 30 s, 72°C for 1 min 20 s, and a final extension of 72°C 
for 10 min. PCR products were visualized via electrophoresis in 
a 2% agarose gel stained with ethidium bromide. PCR products 
were gel purified and concentrated using the Zymo DNA Clean 
and Concentrator-5 kit (Zymo, Irvine, CA, USA). Sanger DNA 
sequencing of PCR amplicons was performed at the DNA 
Sequencing Service Center at the University of Colorado School 
of Medicine.
hai Titers
Assays were performed as previously described (22) using anti-
gens from the Investigator Reagent Resource, Centers of Disease 
Control. Blood was collected in heparinized tubes. Plasma was 
separated by centrifugation and stored in ≥2 aliquots at −20°C. 
On the day of the assay, plasma was incubated at 1:4 in receptor-
destroying enzyme solution (Denka Seiken Co. Ltd.) overnight at 
37°C followed by 30 min at 56°C and subsequently with turkey 
red blood cells (TRBC) at 4°C for 60 min to remove non-specific 
hemagglutinins. Serial twofold dilution of plasma in PBS starting 
at 1:10 were mixed with 4 HA units (HAU) of H1N1 CA 2009, 
H1N1 2014 clinical isolate and B MA 2012 antigens, and TRBC 
in 96-well V-bottom microtiter plates (Corning) for 30  min at 
room temperature. The HAI titer was defined as the reciprocal 
of the last plasma dilution with no HA activity. A titer of 5 was 
assigned to samples in which the first dilution was negative. Each 
run included high- and low-titer positive controls. Assays were 
considered valid if the control HAI titers had less than twofold 
differences from their previously established mean titers.
iga elisa
Thermo Scientific Immulon II HB microwell strips (Thermo 
Scientific) were incubated overnight at 4°C on a shaker with each 
influenza vaccine antigen diluted 1:10 in PBS. Strips were then 
washed with 0.05% Tween 20 in PBS, blocked with 0.5% fetal 
calf serum (FCS) in wash solution for 2 h at room temperature, 
and washed. An aliquot of the M6 transport medium (Remel) in 
which the nasopharyngeal swabs were collected was diluted at 1:2 
and 1:20 (up to 1:300 if needed) in PBS and incubated in duplicate 
wells/virus for 2 h at room temperature. Strips were washed, incu-
bated with biotinylated goat anti-human IgA (Mabtech 3830-4) 
1:1000 in PBS for 1 h at room temperature; washed; and incu-
bated with streptavidin–alkaline phosphatase (Mabtech 3310-8) 
1:1000 in PBS for 1 h at room temperature. After washing, bound 
antibodies were revealed with p-nitrophenyl phosphate and read 
at 490 nm with a Thermo Scientific Multiskan FC ELISA reader 
(Thermo Scientific). The IgA antibody concentration was calcu-
lated by interpolation on the standard curve spanning from 0.08 
to 50 μg/mL of the Human-IgA Elisa kit (Mabtech 3830-1AD-6) 
as per the manufacturer’s instructions. Results were expressed 
in ELISA units (EU)/mL. Nasal swabs that were below the limit 
of detection were assigned a value of 0.01 EU/mL. Positive and 
negative controls were used to validate each run.
neutralizing antibodies
An ELISA-based microneutralization (MN) was performed as 
previously described (23, 24) on plasma collected at baseline and 
post-dose 1. Briefly, serial twofold dilutions of plasma starting 
at 1:10 in phosphate-buffered solution (PBS) were added in 
duplicate to 100 TCID50 of H1N1 CA 2009 or H1N1 2014 clinical 
isolate and 1.5 × 104 MDCK cells in 96-well microtiter plates. Cell 
control and virus control wells were included on each plate. After 
18–22 h of incubation in a humidified atmosphere at 37°C and 5% 
CO2, the cell monolayer was fixed, and the ELISA was performed 
using 100 μL anti-influenza A NP mouse antibodies (Millipore, 
cat. # MAB8257 & MAB8258) followed by goat anti-mouse IgG 
conjugated to horseradish peroxidase (HRP) secondary antibod-
ies (KPL, cat. # 074-1802). Bound antibodies were revealed with 
3,3′,5,5′-tetramethylbenzidine (TMB) substrate. The optical 
density (OD) was measured with a Multiscan FC ELISA reader 
(Thermo Fisher) using a 450 nm filter. The neutralizing titer was 
calculated using the following equation: [median OD of virus 
control wells  +  median OD of cell control wells]/2. Samples 
with discordance larger than 1 dilution between replicates were 
repeated.
iFnγ elisPOT assay
Peripheral blood mononuclear cells (PBMCs) were cryopreserved 
as previously described (25) and stored at ≤−150°C. On the day 
of the assay, cells were thawed slowly as previously described (25). 
ELISPOT assays were performed using commercial ELISpotPlus 
kits (MabTech) as per manufacturer’s instructions. Thawed PBMC 
were allowed to sit overnight and resuspended at 106 PBMC/
mL, in RPMI 1640 with glutamine (Gibco), 10% human AB 
serum (Gibco), 1% penicillin and streptomycin, and 1% HEPES 
buffer. PBMC preparations with viability ≥70%, as measured 
by flow cytometry using the Guava easyCyte 8HT instrument 
(Millipore), were used in these assays. Although viability <70% 
may decrease the results of functional assays, assay results are 
TaBle 1 | Demographics and hiV disease characteristics of the study 
population.






Age in years: median (IQR) 18 (10–23) 10 (7–14) 0.002
Age < 9 years: n (%) 10 (22.2) 22 (40.0) 0.11
Median (IQR) 7 (5–8) 6 (4–7) 0.44
Male sex: n (%) 28 (62.2) 30 (54.5) 0.50
Black race: n (%) 21 (46.7) 9 (16.4)
White race: n (%) 19 (42.2) 45 (81.8) <0.001
Other/unknown race: n (%) 5 (11.1) 2 (3.6)
Hispanic/latino ethnicity: n (%) 7 (15.6) 13 (23.6) 0.48
Received influenza vaccine during 
2011–2012 influenza seasonb: n (%)
36 (80.0) 43 (78.2) 0.88
Received influenza vaccine prior to 
2011–2012 influenza seasonb: n (%)
25 (55.6) 27 (49.1) 0.59
CD4+ cell count/mm3: median (IQR) 645 (550–995)
HIV RNA, copies/mL: median (IQR) 20 (1–940)
Taking cART at study entry: n (%) 38 (84.4)
aYates-corrected chi-square test or Wilcoxon rank-sum test or Fisher exact test.
bNumber and percent of “Yes” responses, missing entries treated as “No.”
cOf the 46 HIV-infected participants, one did not receive vaccine and was excluded 
from the analyses. Of the 56 HIV-uninfected participants, one was lost to follow up after 
the first visit and was also excluded from the analyses.
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stable and unaffected by the viability ≥70 (25–27). Based on our 
assay optimization results, cells were stimulated in duplicate wells 
with 4 HAU/well of H1N1 CA 2009, H1N1 2014 clinical isolate, 
and B MA 2012; 5  μg/mL phytohemagglutinin (PHA; Sigma) 
or unstimulated control. After a 48-h incubation at 37°C in a 
humidified 5% CO2 atmosphere, plates were washed and stained 
with anti-IFNγ mAbs as per manufacturer’s instructions. Spot 
forming cells (SFC) were revealed with colorimetric substrate and 
counted with an Immunospot S5 UV Analyzer (Cell Technologies 
Ltd.). Results were expressed in SFC/106 PBMC after subtracting 
the SFC in unstimulated control wells from those enumerated in 
antigen- or PHA-stimulated wells.
igg/iga Fluorospot
Cryopreserved PBMCs were used for the detection of IgG/
IgA secreting cells (SC). Cells were thawed, counted, and then 
stimulated in RPMI 1640 (Gibco) with 10% fetal bovine serum 
(Gemini Bio-Products), 0.4% penicillin and streptomycin, 1% 
HEPES buffer (Corning Cellgrow), 1 μg/ml of the toll-like recep-
tor agonist R848, and 10 ng/ml IL-2 for 96 h at 37°C, 5% CO2, as 
per conditions previously optimized in our laboratory. PBMCs 
with viability ≥55% were used at 250,000 cells/well in duplicate 
wells of the FluoroSpot IgG/IgA kits (Mabtech Inc.). Assays 
were performed as per manufacturer’s instructions using H1N1 
CA 2009, H1N1 2014 clinical isolate, and B MA 2012 antigens 
at 4 HAU/well, to coat the plates and an ImmunoSpot II (Cell 
Technologies Ltd.) instrument to count the IgG and the IgA SC. 
Results are expressed as SC/106 PBMCs.
statistical analysis
Groups were compared with Yates-corrected chi-square test 
or Fisher exact test for binary or categorical variables, and the 
Wilcoxon rank-sum test for continuous variables. Correlation 
analyses used the Pearson correlation test. Entry nasal IgA con-
centrations were compared with peak response, which occurred 
7–10 days (Visit 3) after immunization for H1N1-09 and H1N1-14 
and at 14–21 days (Visit 4) for BY. Analyses were performed using 
SAS version 9.4 (SAS institute) and Prism version 6 (GraphPad). 
P-values <0.05 were considered significant.
resUlTs
characteristics of the study Population
The study enrolled 46 HIV-infected and 56 uninfected par-
ticipants who received LAIV4 (Table  1). HIV-infected and 
uninfected participants were similar in gender distribution and 
prior influenza vaccination, but differed in age (medians of 18 
and 10  years, respectively) and proportion of blacks (47 and 
16%, respectively). The HIV-infected subjects had median CD4 
cell numbers of 645 cells/μL and median plasma HIV RNA of 20 
copies/mL. Thirty-eight (84.4%) were on cART.
ha genotypes of influenza a h1n1-09  
and h1n1-14
The HA amplicon sequences of the H1N1-09 and H1N1-14 
strains used in the immunologic assays were 100% identical to 
the published HA sequences from these two viruses (GenBank 
accession FJ969540 and KM409098, respectively). The H1N1-14 
HA sequence differed from the published H1N1-09 sequence by 
nine base mismatches over a length of 500 nucleotides. The H1N1-
14 HA sequence encoded the K166Q amino acid substitution 
along with five other non-synonymous mutations (D100N, S188T, 
S206T, D225G, and R226Q); all other base mutations were silent.
T-cell responses to h1n1-09, h1n1-14, 
and BY in hiV-infected and Uninfected 
children after laiV4 2013/2014 
administration
Before vaccination (V1), there was a significant difference 
between H1N1-09 and H1N1-14 effector T-cell responses across 
all participants [median (inter-quartile range = IQR) of 76 (33; 
150) vs. 28 (10; 78) SFC/106 PBMC; p <  0.0001; Figure  1A]. 
The vaccine did not induce a detectable increase at visit 4 
(14–21 days) in responses to the H1N1 viral strains and the dif-
ference between H1N1-09 and H1N1-14 noted before persisted at 
visit 4 after vaccination [median (IQR) of 82 (30; 222) vs. 36 (10; 
68) SFC/106 PBMC; p < 0.0001; Figure 1A]. Vaccination resulted 
in a significant overall increase of the T-cell responses to BY 
[median (IQR) of 116 (49; 207) at entry to 184 (86; 296) SFC/106 
PBMC 14–21  days after vaccination; p <  0.0001; Figure  1A]. 
The SFC/106 PBMC fold-increase from baseline to 14–21  days 
post-vaccination was significantly higher for BY compared to 
H1N1-09 (p ≤ 0.002; Figure 1B).
Compared with HIV-uninfected, HIV-infected participants had 
lower ELISPOT responses to all influenza strains before vaccination 
(p ≤ 0.06; Figure 1A) and lower responses at 14–21 days after vac-
cination to H1N1-09 and H1N1-14 (p ≤ 0.04; Figure 1A), but not 
to BY (Figure 1A). The fold-increase from pre- to post-vaccination 
FigUre 1 | T-cell responses to laiV4 measured by elisPOT. The data were derived from 45 HIV-infected and 55 uninfected individuals. (a) Absolute 
responses in each group of participants, as indicated below the abscissa, at V1 (before vaccination) and V4 (14–21 days after vaccination) and against the viruses 
indicated in the labels of the abscissa. Asterisks (*) indicate significant differences between pre- and post-vaccination. Hash tags (#) indicate significant differences 
between H1N1-09 and H1N1-14. And symbols (&) indicate significant differences between HIV-infected and uninfected participants. (B) Fold-increases from pre- to 
post-vaccination. Asterisks (*) indicated significant differences between H1N1-09 and BY.
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did not differ by HIV status (Figure  1B). Age did not have a 
significant effect on T-cell responses: HIV-infected participants 
<9 years of age had 1.1 and 1.3 median fold-increases to H1N1-09 
and BY, respectively, while HIV-infected participants ≥9 years of 
age had 1.0 and 1.7, respectively. Corresponding numbers for HIV-
uninfected participants were 1.1 and 1.3 and 1.0 and 1.4.
B-cell responses to h1n1-09, h1n1-14, 
and BY in hiV-infected and Uninfected 
children
Before vaccination, IgG B-cell memory responses measured by 
FluoroSpot were significantly higher for H1N1-09 compared with 
H1N1-14 across all participants [median (IQR) of 8 (4; 16) vs. 4 
(2; 11) IgG SC/106 PBMC; p =  0.002; Figure 2A]. Vaccination 
significantly increased H1N1-14 (p  =  0.007) but not H1N1-
09 IgG memory B cells across all participants, but responses 
remained higher for H1N1-09 compared with H1N1-14 at visit 
4, 14–21 days after vaccination [median (IQR) of 8 (4; 18) vs. 6 (4; 
18) IgG SC/106 PBMC; p = 0.04; Figure 2A]. IgG B-cell memory 
to BY significantly increased from pre- to post-vaccination 
(14–21 days) across all participants [median (IQR) of 4 (2; 14) 
vs. 12 (4; 26); p < 0.0001; Figure 2A]. IgG memory B cell fold-
increase from pre- to post-vaccination was significantly higher 
for BY compared with H1N1-09 (p = 0.007; Figure 2B).
HIV status was not associated with any differences in the propor-
tion of IgG memory B cells before or 14–21 days after vaccination 
for either of the H1N1 strains. At entry, BY-specific IgG SC were 
similar in HIV-infected and uninfected participants, but 14–21 days 
after vaccination IgG SC of HIV-infected were lower than those of 
uninfected vaccinees [median (IQR) of 9 (0; 21) vs. 14 (6; 28) IgG 
SC/106 PBMC; p = 0.04; Figure 2A]. Age did not have a significant 
effect on IgG memory responses to H1N1 or BY (not depicted).
Most of the participants did not have detectable IgA memory 
B cells before or after vaccination for any of the influenza strains 
regardless of age and HIV status. This precluded any meaningful 
statistical analyses.
hai antibody responses to h1n1-09, 
h1n1-14, and BY
Before vaccination, HAI titers did not significantly differ between 
H1N1-09 and H1N1-14 across all participants [GMT (95% CI) 
of 45 (35; 59) vs. 48 (36; 65); Figure  3A]. At visit 4 after vac-
cination (14–21 days), HAI titers similarly increased against both 
strains of H1N1 (p ≤ 0.02; Figures 3A,B). BY-specific HAI titers 
significantly increased from pre- to 14–21 days post-vaccination 
[GMT (95% CI) of 8.8 (7.7; 10) to 10.9 (9.4; 12.7), p = 0.0002; 
Figure  3A]. The fold-increases in titers were similar for BY 
compared with H1N1-09 (Figure 3B).
Hemagglutination inhibition titers pre- and 14–21  days 
post-vaccination did not differ by HIV status for any of the three 
influenza strains studied. Age <9 years was associated with lower 
baseline BY-specific HAI titers and fold-increase (p = 0.0003 and 
0.04, respectively; not depicted).
neutralizing antibody responses  
to h1n1-09 and h1n1-14
Before vaccination, neutralizing antibody titers were higher for 
H1N1-09 than H1N1-14 across all participants [GMT (95% CI) 
of 153 (133; 176) vs. 131 (105; 164); p = 0.03; Figure 4A] and in 
HIV-uninfected participants [GMT (95% CI) of 168 (134; 209) 
FigUre 3 | antibody responses to laiV4 measured by hai. The data were derived from 45 HIV-infected and 55 uninfected individuals. (a) Absolute responses 
in each group of participants, as indicated below the abscissa, at V1 (before vaccination) and V4 (14–21 days after vaccination) and against the viruses indicated in 
the labels of the abscissa. Asterisks (*) indicate significant differences between pre- and post-vaccination. (B) Fold-increases from pre- to post-vaccination. There 
were no significant differences across viruses or by HIV status.
FigUre 2 | igg memory B-cell responses to laiV4 measured by elisPOT. The data were derived from 45 HIV-infected and 55 uninfected individuals. (a) 
Absolute responses in each group of participants, as indicated below the abscissa, at V1 (before vaccination) and V4 (14–21 days after vaccination) and against the 
viruses indicated in the labels of the abscissa. Asterisks (*) indicate significant differences between pre- and post-vaccination. Hash tags (#) indicate significant 
differences between H1N1-09 and H1N1-14. And symbols (&) indicate significant differences between HIV-infected and uninfected participants. (B) Fold-increases 
from pre- to post-vaccination. Asterisks (*) indicated significant differences between H1N1-09 and BY.
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vs. 121 (87; 169); p = 0.04; Figure 4A]. Neutralizing titers against 
both H1N1 strains significantly increased at visit 4 (14–21 days 
after vaccination) regardless of HIV status or age (p  ≤  0.04; 
Figure 4B). However, after vaccination, titers against H1N1-09 
were marginally higher overall and significantly higher in HIV-
uninfected vaccinees (p of 0.06 and 0.02, respectively; Figure 4A). 
Age did not have an effect on neutralizing antibody titers.
nasal iga antibody responses  
to h1n1-09, h1n1-14, and BY
Overall, before vaccination, influenza-specific IgA concentra-
tions in nasal secretions were similar between H1N1-09 and 
H1N1-14 and significantly increased from pre- to post-vacci-
nation with a peak at visit 3, 7–10 days after vaccination [GMC 
(95% CI) of 2.3 (2.6; 3.3) to 3.7 (3.1; 4.5), p < 0.0001; and 3.5 
FigUre 4 | neutralizing antibody responses to laiV4. The data were derived from 45 HIV-infected and 55 uninfected individuals. (a) Absolute responses in 
each group of participants, as indicated below the abscissa, at V1 (before vaccination) and V4 (14–21 days after vaccination) and against the viruses indicated in the 
labels of the abscissa. Asterisks (*) indicate significant differences between pre- and post-vaccination. Hash tags (#) indicate significant differences (p < 0.05) and 
strong trends (0.05 ≤ p < 0.1) between H1N1-09 and H1N1-14. (B) Fold-increases from pre- to post-vaccination.
FigUre 5 | nasal iga antibody responses to laiV4 measured by elisa. The data were derived from 45 HIV-infected and 55 uninfected individuals. (a) 
Absolute responses in each group of participants, as indicated below the abscissa, at V1 (before vaccination) and at the maximum response, which was V3 
(7–10 days after vaccination) for H1N1 viruses and V4 (14–21 days after vaccination) for BY. The viruses are indicated in the labels of the abscissa. Asterisks (*) 
indicate significant differences between pre- and post-vaccination. And symbols (&) indicate significant differences between HIV-infected and uninfected participants. 
(B) Fold-increases from pre- to post-vaccination. Asterisks (*) indicated significant differences between H1N1-09 and BY.
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(2.8; 4.3) vs. 4.2 (3.3; 5.2), p =  0.01, respectively; Figure 5A]. 
BY IgA significantly increased from baseline to post-vaccination 
reaching its peak at visit 4, 14–21 days after vaccination [GMC 
(95% CI) of 2.4 (1.9; 3.2) to 4.6 (3.5; 5.9), p < 0.0001; Figure 5A]. 
IgA fold-increases from pre- to post-vaccination were similar 
for H1N1-09 and H1N1-14, but were significantly higher for 
BY compared with H1N1-09 across all participants (p = 0.005; 
Figure 5B).
There were no significant differences in nasal IgA concentra-
tions against H1N1 or BY strains by HIV status. Age <9 years 
was significantly associated with lower fold-increases and post-
vaccination peak concentrations to BY (p ≤ 0.009; not depicted).
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DiscUssiOn
In this first comparison of the immunogenicity of LAIV4 admin-
istered in parallel to HIV-infected and uninfected children and 
youth 2–25 years of age, we showed that HIV-infected vaccinees 
with average CD4 cell numbers >500  cells/μl and low HIV 
replication on cART mounted cellular, humoral, and mucosal 
responses comparable to those of uninfected controls. No differ-
ences were observed in the HAI, neutralizing and mucosal IgA 
or in the T-cell responses to LAIV4. Compared with uninfected 
controls, HIV-infected participants had lower T-cell immunity 
to H1N1-09 before vaccination and because the vaccine did not 
elicit a T-cell response to H1N1-09, the difference persisted after 
vaccination. By contrast, T-cell immunity to BY, which was also 
lower at baseline in HIV-infected compared with uninfected par-
ticipants, significantly increased after vaccination removing any 
differences. The significance of the low baseline T-cell immunity 
against the influenza vaccine viruses in HIV-infected individuals 
compared with uninfected controls needs to be further eluci-
dated. Since 80% of the HIV-infected and 78% of the uninfected 
participants received IIV in the previous influenza season and 
there were no differences in baseline HAI titers by HIV status, the 
difference in T-cell immunity might reflect lower T-cell responses 
to IIV in HIV-infected compared with uninfected vaccinees 
and/or accelerated loss of the T-cell immunity in HIV-infected 
children and youth.
Although most immune responses to LAIV4 had similar mag-
nitude in HIV-infected and uninfected participants, probably as a 
result of the immune reconstitution or preservation and low viral 
replication on cART, residual defects persisted in the memory 
B-cell responses. Only the BY component of LAIV4 generated 
significant increases in IgG memory B cells. At entry, the IgG 
memory B-cell immunity to BY was similar in HIV-infected 
compared with uninfected groups, but after vaccination, HIV-
infected participants had lower IgG memory B-cell immunity to 
the BY. This finding is in accordance with previous reports, indi-
cating that HIV-infected individuals maintain B-cell functional 
and/or phenotypic defects even after other immune responses 
improve as a result of cART (28, 29). Memory B-cell responses 
to influenza were shown to play an important role for heterotypic 
cross-reactivity (30). Therefore, in years where the vaccine and 
circulating strains of influenza are well matched, this might not 
be problematic.
We compared the overall immunogenicity of BY and H1N1 
components of LAIV4, because differences in the immuno-
genicity of the vaccine viruses had the potential to introduce 
biases in the primary outcome analyses as discussed above. 
The data showed lower T cell and nasal IgA responses to H1N1 
compared with BY. To minimize assay variability, all the viruses 
and antigens used in the ELISPOT and ELISA contained 
similar numbers of HAU and all samples of each participant 
were assayed against all viruses in the same run. In general, 
low baseline immunologic variables have been associated with 
higher fold-increases after vaccination (21). This may have con-
tributed to the differences observed in the IgA responses, but 
not in ELISPOT responses where baseline results were higher 
for BY compared to H1N1.
Age is an important determinant of responses to influenza 
vaccines such that it is recommended that children under the age 
of 9 years to receive 2 doses of influenza vaccines when immu-
nized for the first time. In this study, HIV-infected participants 
were significantly older than uninfected controls. This difference 
was at least partially mitigated by requiring all participants to 
have a history of influenza vaccination in ≥1 year prior to study 
entry. Nevertheless, we found that age <9 years was associated 
with decreased nasal IgA and HAI responses to BY. The B 
Massachusetts 2012 BY was first introduced into the vaccine 
in 2013/2014, which is likely to have contributed to the lower 
baseline responses in children <9 years of age. However, our data 
revealed that children <9 years also had decreased responses to 
the newly introduced vaccine component in spite of vaccination 
against influenza in previous years. This novel piece of informa-
tion has to be further confirmed.
In the 2013–2014 influenza season, H1N1 became again the 
predominant strain to cause symptomatic disease, hospitaliza-
tion, and death (31) after having circulated and being included in 
influenza vaccines since 2009, which suggested that the immune 
memory raised by H1N1-09 infection or vaccination might not 
have conferred optimal protection against the circulating H1N1-
14. Compared with the H1N1-09 vaccine virus, the H1N1-14 
accumulated an equal number of mutations with that observed 
in H3N2, although in the case of H3N2 the mutations were 
associated with 2 antigenic drifts (18). Furthermore, a muta-
tion (K166Q) located in a B-cell epitope targeted by human 
neutralizing antibodies (19) was present in the overwhelming 
majority of the H1N1 strains circulating in 2013–2014 and also 
in the clinical H1N1-14 isolate that we used in our assays. In 
support of the hypothesis that the antigenic differences between 
H1N1-09 and H1N1-14 were immunologically relevant, our 
data showed significantly lower immune responses before vac-
cination against H1N1-14 compared to H1N1-09 mediated by 
neutralizing antibodies, T cells and IgG memory B cells. While 
the differences in antibody and memory B-cell responses might 
be explained by the K166Q mutation in the HA, it is unlikely that 
this mutation also accounted for the T-cell responses differences. 
T cell recognize short epitopes, more frequently located in the 
nucleocapsid proteins than in the HA. Therefore, we would have 
to assume that H1N1-09 and H1N1-14 differed in other peptides 
in addition to the HA. It is also notable that the neutralizing 
antibody titers were affected by the HA mutation, but the HAI 
titers were not. This suggests a higher specificity of the neutral-
izing compared with hemagglutination assay. The differences 
between the H1N1-09 and BY strains persisted after vaccina-
tion, either because of the low immunogenicity of LAIV4 against 
H1N1, as in the case of T- and memory B-cell immunity, or in 
spite of the responses generated by the vaccine, as in the case 
of the neutralizing antibodies. Taken together, the data suggest 
that the antigenic differences between H1N1-09 and H1N1-14 
might have further contributed to the low effectiveness of LAIV4 
against H1N1 in 2013–2014.
Of note, the HAI titers before or after vaccination did not 
differ between H1N1-09 and H1N1-14, and the fold-increases 
also did not differ by vaccine virus, HIV status, or age. In 
contrast to ELIPOT, neutralization and nasal IgA detected ≥1 
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differences in the responses to LAIV4 across hosts or viruses. 
This may be specific to LAIV among all influenza vaccines, 
because HAI responses generated by LAIV tend to be lower than 
those generated by subunit vaccines. However, it is important 
to follow up on this observation in additional studies, because 
HAI is currently the benchmark for evaluating new influenza 
vaccines.
Of most important clinical significance, we found that LAIV4 
was equally immunogenic in HIV-infected children with high 
CD4 cell numbers and low viral replication on cART as in 
uninfected children with respect to T-cell-mediated and mucosal 
IgA responses. These immune response categories were shown 
to correlate with the LAIV-conferred protection (8–10). This 
indicates that LAIV is likely to have similar effectiveness in HIV-
infected children with immune preservation or reconstitution 
on cART and uninfected children. Another clinically important 
finding was that children <9 years of age, despite past influenza 
immunization, had decreased responses to a strain of influenza 
newly introduced into the vaccine.
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